OrbiMed’s Kezar Life Sciences KZR Stock Holding History

OrbiMed’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-192,700	Closed	-$752K	–	119
2025 Q3	$752K	Hold	192,700	–	–	0.02%	105
2025 Q2	$883K	Hold	192,700	–	–	0.02%	94
2025 Q1	$940K	Hold	192,700	–	–	0.02%	102
2024 Q4	$1.29M	Hold	192,700	–	–	0.03%	109
2024 Q3	$1.49M	Hold	192,700	–	–	0.03%	115
2024 Q2	$1.16M	Hold	192,700	–	–	0.02%	110
2024 Q1	$1.74M	Hold	192,700	–	–	0.03%	106
2023 Q4	$1.83M	Sell	192,700 -353,600	-65%	-$3.11M	0.04%	98
2023 Q3	$6.5M	Hold	546,300	–	–	0.14%	94
2023 Q2	$13.4M	Hold	546,300	–	–	0.24%	79
2023 Q1	$17.1M	Buy	546,300 +87,868	+19%	+$5.08M	0.34%	72
2022 Q4	$32.3M	Buy	458,432 +281,262	+159%	+$20.9M	0.62%	55
2022 Q3	$15.3K	Buy	177,170 +35,180	+25%	+$3.42M	0.28%	72
2022 Q2	$11.7K	Buy	+141,990	New	+$12.5M	0.21%	86
2021 Q4	–	Sell	-115,000	Closed	-$9.94M	–	166
2021 Q3	$9.94M	Buy	115,000 +59,281	+106%	+$3.92M	0.11%	129
2021 Q2	$3.03M	Buy	+55,719	New	+$3.16M	0.03%	155

Other funds holding KZR

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

OrbiMed's KZR Position: Q4 2025 in Review

OrbiMed sold out of Kezar Life Sciences (KZR) in Q4 2025, closing a stake of 192,700 shares — an estimated $752K sold.

OrbiMed first reported a position in KZR in Q2 2021 and held it in 16 quarters. The position peaked at $32.3M in Q4 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2025.

OrbiMed reported no remaining Kezar Life Sciences position as of Q4 2025 after selling out during the quarter.
OrbiMed sold 192,700 Kezar Life Sciences shares in Q4 2025, an estimated $752K.
OrbiMed first reported a position in Kezar Life Sciences in Q2 2021 and held it in 16 quarters.
OrbiMed's Kezar Life Sciences position peaked at $32.3M in Q4 2022.
43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2025.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.